BioStrand Revolutionizes Sequence Retrieval Via NLP And Database Fusion

 


ImmunoPrecise Antibodies Ltd.'s BioStrand subsidiary made a significant stride by unveiling a groundbreaking white paper, "New Paradigm for Biological Sequence Retrieval," pioneering HYFT-based methodology. This approach, trumping the widely used BLAST algorithm, tokenizes sequences into unique HYFT patterns, offering enhanced precision and scalability without compromising data accuracy. Dirk Van Hyfte, BioStrand's Co-Founder, believes this method, harnessing increased sequence data, will drive discourse and collaboration in bioinformatics.

In addition, BioStrand launched LENSai, a cutting-edge AI platform that integrates a comprehensive knowledge graph linking 25 billion relationships across biological data, enabling a deeper understanding of genetic, structural, and functional interconnections. Leveraging ontology-driven NLP and AI-driven LLMs, LENSai harmonizes syntactic and semantic data, propelling drug discovery and development.

As part of the IPA Family, ImmunoPrecise Antibodies Ltd. leverages advanced AI and systems biology in bioplatform-based antibody discovery. Their suite of services spans therapeutic biologics discovery, development, and out-licensing, supporting partners in addressing complex targets. Visit www.ipatherapeutics.com for more details.

Read More - https://www.techdogs.com/tech-news/business-wire/biostrand-unveils-a-revolutionary-approach-to-biological-sequence-retrieval-a-fusion-of-natural-language-processing-and-database-research

Comments

Popular posts from this blog

Orlagh Neary, Former VP Of Quantum Ecosystem Engagement And GTM At Microsoft On Building Scalable And Safe AI And Quantum

SiFive Announces Differentiated Solutions For Generative AI And ML Applications

Varun Srinivas Founder & CEO of Therix.ai and Co-Founder at Coditas on Building Real-World AI Solutions